.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XD06_Efaproxiral.Efaproxiral

Information

Efaproxiral (RSR13) is an allosteric effector of hemoglobin, designed to decrease hemoglobin oxygen affinity and thereby enhance tissue oxygenation. It was primarily investigated as a radiosensitizer for treatment of hypoxic tumors, especially in patients with brain metastases. Efaproxiral is not an approved drug and its clinical development has been discontinued.

Pharmacokinetics

Parameters derived from published phase I study in adult cancer patients (n=43), both sexes, median age around 57 years, after intravenous administration.

References

Revisions

• 06/2025 initial generated model